Pioglitazone is a thiazolidinedione. It activates a nuclear receptor called PPAR-gamma, which changes how fat cells behave and makes muscle, liver and fat tissue more sensitive to insulin. That is a genuinely different mechanism from every other diabetes drug - it tackles insulin resistance directly rather than working around it. It fell out of favour for reasons that were partly justified and partly not, and it retains a specific usefulness that nothing else quite replaces.
Follow the instructions on your label. This guide contains no doses.
What it does well
Pioglitazone lowers HbA1c durably - in long-term comparisons, glucose control on it deteriorated more slowly than on metformin or a sulfonylurea.
It does not cause hypoglycaemia on its own, because it does not stimulate insulin release.
It is particularly useful in people with marked insulin resistance, and in non-alcoholic fatty liver disease, where it is one of the few treatments with evidence of improving the liver histology. It also reduced recurrent stroke risk in one trial of insulin-resistant people after stroke.
See metformin and empagliflozin for the drugs that displaced it.
Heart failure is the absolute limit
Pioglitazone causes fluid retention, which can precipitate or worsen heart failure.
It is contraindicated in anyone with heart failure or a history of it. That is not a caution - it is a hard limit.
Report promptly increasing breathlessness, swollen ankles, or rapid weight gain, which suggest fluid retention.
The risk is greater when combined with insulin, so that combination is used cautiously and monitored closely.
The bladder cancer question
An early signal suggested a possible small increase in bladder cancer risk with longer use, and it led to withdrawal in some countries.
Subsequent larger studies have been inconsistent, and several found no significant association. The current position is that any risk is small and uncertain, but it is not fully dismissed.
It is avoided in anyone with active bladder cancer or a history of it, and in anyone with unexplained blood in the urine that has not been investigated.
Report blood in the urine, pain on passing urine, or urgency rather than assuming it is a urinary infection.
Fractures
Pioglitazone increases fracture risk, particularly in women and particularly at peripheral sites - wrist, hand, foot and ankle.
The mechanism relates to its effect on bone marrow stem cells, which are directed towards fat rather than bone.
That makes it a poor choice for anyone with osteoporosis or significant fracture risk. See medicines and bone health.
Weight gain
Weight increases on pioglitazone, partly from fluid and partly from fat redistribution - though the fat is deposited subcutaneously rather than around the organs, which is the less harmful pattern.
It is still weight gain, and in the era of medicines that produce substantial weight loss it is a real disadvantage. See medicines and your weight.
It works slowly
Because it works by changing gene expression rather than by a direct pharmacological action, pioglitazone takes weeks to months to reach its full effect.
Judging it at four weeks is judging it too early. Expect a review at around three to six months.
Monitoring
Liver function before starting and periodically - an older drug in the same class was withdrawn for liver toxicity, and although pioglitazone has not shown the same problem, the caution persists.
Report jaundice, dark urine, persistent nausea or abdominal pain - see medicines and your liver.
Weight, signs of fluid retention, and HbA1c are all tracked - see monitoring long-term medicines.
Other points
Macular oedema - fluid at the back of the eye - is a recognised effect. Report any change in vision.
In women with polycystic ovary syndrome, improving insulin sensitivity can restore ovulation, so someone who was not conceiving may become fertile. Contraception should be considered if pregnancy is not wanted.
Pioglitazone is not used in pregnancy.
Interactions
Pioglitazone is cleared partly by CYP2C8, so gemfibrozil raises its levels substantially and the combination usually needs a dose reduction.
Rifampicin lowers levels. Combining pioglitazone with insulin increases the fluid retention and heart failure risk. Tell your prescriber everything you take, including anything bought over the counter.
Where it fits now
It has been overtaken by the SGLT2 inhibitors and GLP-1 agonists, which lower glucose while also protecting the heart and kidneys and causing weight loss rather than gain.
Pioglitazone remains a reasonable option for someone with marked insulin resistance, no heart failure, no fracture risk, and where cost matters - and it is cheap, which is not nothing. It is also the option with the best evidence in fatty liver disease.
More on what medicines are prescribed for in the Conditions section, including Glimepiride: Sulfonylureas and Hypo Risk.